Additional 3 Years of Adjuvant Imatinib Maintenance Reduces

Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST

Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST

onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

France , , University Claude Bernard , Novartis , Cancer Centre Of Lyon , Astrazeneca , Glaxosmithkline , National Comprehensive Cancer Network , Bristol Myers Squibb , Jean Yves Blay , Comprehensive Cancer Centre , Eligibility Criteria , Task Force , Deep Dive Into , Innate Pharma ,